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Abstract 20 
Introduction The way in which tobacco smoking increases the risk of preterm labor remains 21 
uncertain.  Altered prostaglandin metabolism is one potential mechanism.  22 
Methods Proteins in fetal membrane samples (amniochoriodecidua) from 20 women were relatively 23 
quantified using Tandem Mass Tagging nano-liquid chromatography mass spectrometry.  24 
 2 
 
Results Prostaglandin synthases and two enzymes involved in prostaglandin degradation, 1 
hydroxyprostaglandin dehydrogenase (HPGD) and CBR1, were detected by the mass spectrometer. 2 
The expression of HPGD was significantly lower in smokers relative to non-smokers (0.43 fold, 3 
p=0.016). There was no effect of labor, inflammatory status or gestational age on the HPGD levels.  4 
Discussion We describe for the first time an association between maternal smoking and HPGD 5 
expression. We propose that reduced expression of HPGD is one mechanism through which smoking 6 
may contribute to preterm labor. Lower levels of this enzyme, key to metabolising prostaglandins, 7 
may result in higher levels of prostaglandins and therefore precipitate labor prematurely.  8 
 9 
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(15-hydroxyprostaglandin dehydrogenase). 12 
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Introduction 14 
Smoking is known to increase the risk of both spontaneous and iatrogenic preterm birth, but the 15 
association with spontaneous preterm birth is stronger [1]. There are many potential pathways 16 
through which smoking may cause premature labor [2]. These include nicotine-induced 17 
vasoconstriction [3, 4], carbon monoxide-induced fetal hypoxia [5, 6], cadmium disruption of calcium 18 
signalling [7, 8], altered steroid hormone production [9, 10], changed responses to oxytocin [11, 12]  19 
and altered prostaglandin (PG) production and metabolism [13].  20 
The use of animal models to investigate potential mechanisms from preterm birth has shifted from 21 
endocrine pathways (e.g. cortisol induced placental progesterone withdrawal in sheep; luteolysis in 22 
rats) to inflammatory models e.g. lipopolysaccharide (LPS) induced proinflammatory response in 23 
mice [14]. The induction of premature labor by LPS in mice has highlighted the importance of genes 24 
involved in the regulation of connective tissue remodelling and tensile strength such as tenascin 25 
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(Tnc) and thrombospondin (Thhbs2) as well as the activity of several matrix metalloproteinases [15]. 1 
These advances have contributed to our understanding of cervical ripening and dilatation 2 
mechanisms associated with spontaneous preterm labor.  3 
Amnion choriodecidual (ACD) cells, especially tissue macrophages, may have a role in spontaneous 4 
preterm labor by promoting the release of prostaglandins and proinflammatory cytokines [16]. 5 
Whilst the amnion produces large quantities of PGE2, the chorion produces both PGE2 and PGF2 as 6 
well as an important modulator of PG activity, 15-hydroxy PG dehydrogenase (HPGD) [17].  7 
Proinflamatory cytokines (e.g. interleukin 1, tumour necrosis factor-α) promote upregulation of 8 
prostaglandin synthase enzymes in the fetal membranes and decidua [18]. Inflammation of the fetal 9 
membranes is much more common in preterm deliveries than at term: Acute chorioamnionitis has 10 
been detected in 30% of preterm pregnancies but only in 5% of term pregnancies [19, 20]. 11 
Chorioamnionitis causes early preterm labour by increasing prostaglandin production in ACD [21];  12 
however the mechanism of labour in spontaneous  preterm deliveries without signs of infection or 13 
inflammation remains unexplained. There is a complex interaction among maternal and fetal factors 14 
at the ACD interface; these involve prostaglandins, cytokines, growth factors and reactive oxygen 15 
species. These pathways are superimposed on genetic predisposition and immune defence 16 
mechanisms involved in the regulation of human labour [22]. The breakdown of maternal-fetal 17 
tolerance at the decidua/fetal membrane interface can disrupt the production of chemokines and 18 
cytokines (IL-1α, TNFα), as well as prostaglandins, reactive oxygen radicals and proteases. These 19 
products can initiate uterine contractions directly and/or provoke cervical changes and premature 20 
rupture of the membranes [23]. 21 
Whilst smoking has been shown to affect the levels of prostaglandins, such as PGF2, PGE2, 22 
prostaglandin D2 and the prostacyclin metabolite 6-ketoprostaglandin F1 [13] in amniotic fluid, the 23 
effect of smoking on protein expression within the fetal membranes and decidua has not previously 24 
been considered. 25 
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Here we present proteomic data using gel-free separation methods that allow the identification and 1 
measurement of relative changes of thousands of proteins simultaneously. The results show a very 2 
significant effect of smoking on the amnion/chorion/decidual proteome; enormous disruption 3 
caused by inflammatory infiltration and changes specifically associated with spontaneous term and 4 
preterm labor.  5 
Materials and methods 6 
Tissue collection 7 
Fetal membrane tissue (combined amnion-chorion-decidua parietalis, ACD) was obtained 8 
immediately after delivery from women who were not in labor (NL; no uterine activity or cervical 9 
change) and were undergoing planned Caesarean section with the following indications: previous 10 
Caesarean section, previous obstetric anal sphincter injury or pelvic outlet obstruction. ACD samples 11 
were also obtained from women after vaginal deliveries following spontaneous labor (L). Cases were 12 
further divided into either term (TL or TNL; 37-42 weeks gestational age) or preterm (PTL; less than 13 
35 weeks of gestation). PTL cases were further subdivided into those with evidence of 14 
inflammation/infection (PTLi) and those without (PTLn), based on clinical features of the women 15 
(pyrexia, offensive liquor or uterine tenderness) or histological determination of the presence of 16 
leucocyte infiltration in the fetal membranes (chorioamnionitis), decidua (deciduitis) or placenta 17 
(intervillositis), with or without maternal pyrexia or uterine tenderness. Smoking was determined by 18 
self-report. Tissues were snap-frozen in liquid nitrogen and stored at -80°C. This study was approved 19 
by the NHS South West Research Ethics Committee. All patients gave written informed consent.  20 
Paraffin-embedded sections for histopathology 21 
Tissues were rinsed in sterile saline and fixed in 4% phosphate buffered formaldehyde. After 24 22 
hours fixation, tissues were washed with sterile saline and processed using Leica JUNG TP 1050 23 
Tissue processor into paraffin wax and sectioned into 3m thickness.  24 
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Tissue homogenisation 1 
Frozen tissue samples were homogenised in RIPA (Radio-ImmunoPrecipitation Assay) lysis buffer 2 
(50mM Tris pH 7.5, 150mM sodium chloride, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 1 x 3 
Complete protease inhibitor cocktail (Roche), 1 x PhosSTOP protease inhibitor cocktail (Roche)) at 4 
∼200 mg/ml using a Polytron homogeniser at room temperature. Homogenates were immediately 5 
cleared by centrifugation at 16 000 g for 15 min at 4°C. Protein concentration was determined using 6 
the Pierce™ BCA assay kit (ThermoFisher Scientific, Loughborough, UK). The supernatants were 7 
adjusted by addition of further RIPA buffer to make each sample 175 l at 2 mg/ml. 8 
Tandem Mass Tag (TMT) Labelling and cation exchange chromatography 9 
Aliquots of 100 µg of six samples per experiment were digested with trypsin (2.5 µg trypsin per 100 10 
µg protein; 37°C, overnight), labelled with Tandem Mass Tag (TMT) sixplex reagents according to the 11 
manufacturer’s protocol (Thermo Fisher Scientific, Loughborough, UK) and the labelled samples 12 
pooled. 13 
A 50 µg aliquot of the pooled sample was used, evaporated to dryness and re-suspended in Buffer A 14 
(10 mM KH2PO4, 25% MeCN, pH3) prior to fractionation by strong cation exchange using an Ettan LC 15 
system (GE Healthcare).  In brief, the sample was loaded onto a PolysulphoethylA column (100 x 2.1 16 
mm, 5 µm, 200 A; PolyLC Inc.) in buffer A and peptides eluted with an increasing gradient of buffer B 17 
(10 mM KH2PO4, 25% MeCN, 1 M KCl, pH3) from 0 to 100% over 30 minutes. The resulting fractions 18 
were evaporated to dryness, re-suspended in 5% (v/v) formic acid and then desalted using SepPak 19 
cartridges according to the manufacturer’s instructions (Waters, Milford, Massachusetts, USA).  20 
Eluate from the SepPak cartridge was again evaporated to dryness and re-suspended in 1% formic 21 
acid prior to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid Mass Spectrometer.   22 
Nano-liquid chromatography mass spectrometry (Nano-LC MS) 23 
The cation exchange fractions were further fractionated using an Ultimate 3000 nanoHPLC system in 24 
line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  In brief, peptides in 1% 25 
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(v/v) formic acid were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Scientific). 1 
After washing with 0.5% (v/v) acetonitrile 0.1% (v/v) formic acid, peptides were resolved on a 250 2 
mm × 75 μm Acclaim PepMap C18 reverse phase analytical column (Thermo Scientific) over a 150 3 
minute organic gradient, using 7 gradient segments (1-6% solvent B over 1 minute, 6-15% B over 58 4 
minutes, 15-32% B over 58 minutes, 32-40% B over 5 minutes, 40-90% B over 1 minute, held at 90% 5 
B for 6 minutes and then reduced to 1% B over 1 minute) with a flow rate of 300 nl/minute.  Solvent 6 
A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides 7 
were ionised by nano-electrospray ionisation at 2 kV using a stainless-steel emitter with an internal 8 
diameter of 30 μm (Thermo Scientific) and a capillary temperature of 275°C.  9 
 10 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 11 
2.0 software (Thermo Scientific) and operated in data-dependent acquisition mode using an SPS-12 
MS3 workflow.  FTMS1 spectra were collected at a resolution of 120 000, with an automatic gain 13 
control (AGC) target of 400 000 and a maximum injection time of 100 ms. The top ten most intense 14 
ions were selected for MS/MS.  Precursors were filtered according to charge state (to include charge 15 
states 2-6) and with monoisotopic precursor selection. Previously interrogated precursors were 16 
excluded using a dynamic window (40s +/-10ppm). The MS2 precursors were isolated with a 17 
quadrupole mass filter set to a width of 1.2m/z. ITMS2 spectra were collected with an AGC target of 18 
5000, max injection time of 70 ms and CID collision energy of 35%. 19 
For FTMS3 analysis, the Orbitrap was operated at 30 000 resolution with an AGC target of 50 000 20 
and a max injection time of 105 ms.  Precursors were fragmented by high energy collision 21 
dissociation (HCD) at a normalised collision energy of 55% to ensure maximal TMT reporter ion yield.  22 
Synchronous Precursor Selection (SPS) was enabled to include up to 10 MS2 fragment ions in the 23 
FTMS3 scan. The method allowed us to analyse the full proteome for each sample of ACD. 24 
Data Analysis 25 
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The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo 1 
Scientific) and searched against the UniProt Human database (downloaded 08/11/14: 126385 2 
entries) using the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 10 ppm, and 3 
MS/MS tolerance was set at 0.6 Da.  Search criteria included oxidation of methionine (+15.9949) as a 4 
variable modification and carbamidomethylation of cysteine (+57.0214) and the addition of the TMT 5 
6Plex mass tag (+229.163) to peptide N-termini and lysine as fixed modifications. Searches were 6 
performed with full tryptic digestion and a maximum of one missed cleavage was allowed.  The 7 
reverse database search option was enabled and all peptide data was filtered to satisfy false 8 
discovery rate (FDR) of 5%.  9 
Uniprot Human Database (http://www.uniprot.org/uploadlists/) was used to convert the accession 10 
numbers produced by the Proteome Discoverer software into Human Genome Organisation (HUGO) 11 
gene names. Where the accession numbers were not recognised by UniProt, the ‘description’ field 12 
output from Proteome Discoverer was analysed to find the ‘GN’ code where given and the HUGO 13 
gene name identified in this way.  14 
Statistics 15 
Median values are given unless otherwise stated and groups compared using the Kruskall-Wallis H 16 
test. Differences were deemed statistically significant for p values less than 0.05.  17 
Results  18 
ACD samples were collected from 20 women. The clinical characteristics for the placentas studied 19 
can be seen in table 1. 20 
Table 1 Clinical characteristics for the 20 women giving ACD samples 21 
Group n Median 
gestational age 
at delivery in 
weeks (range) 
M:F Median 
birthweight 
in kg (IQR) 
Median length 
of labor in 
hours (IQR) 
Median 
delivery to 
processing 
interval in mins 
(IQR) 
All 20 36+3  8:12 2.61  3.2  114  
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(24+1 - 40+0) 
 
(1.75 - 3.43) (2.5 - 5.6) (73 - 359) 
Term, no 
labor  
(TNL) 
5 39+1 
 (39+0 - 39+4) 
1:4 3.22  
(3.00 - 3.39) 
n/a 44  
(33 - 60) 
Term, labor 
(TL) 
5 39+5  
(38+0 - 40+0) 
 
3:2 3.45 
 (3.43 - 3.53) 
3.6  
(2.8 - 6.9) 
112  
(98 - 165) 
Preterm 
labor, no 
infection 
(PTLu) 
4 33+1 
(31+5 - 34+4) 
2:2 1.86  
(1.75 - 2.02) 
2.2  
(1.1 - 3.7) 
136  
(49 - 388) 
Preterm 
labor, 
infection 
(PTLi) 
6 27+4  
(24+1 - 34+6) 
2:4 1.01  
(0.73 - 2.27) 
5.8  
(3.1 - 7.9) 
97  
(36 - 565) 
Smoker 7 34+4  
(24+1 - 39+5) 
 
3:4 1.90  
(0.94 - 3.15) 
4.4  
(1.4 -8.9) 
44  
(36 - 503) 
Non-smoker 13 38+0  
(26+0 - 40+0) 
 
5:8 3.22  
(1.94 - 3.46) 
3.6  
(2.7 - 4.6) 
84  
(49 - 171) 
 1 
A combined total of 4709 proteins were detected within the 20 ACD samples. There were 243 2 
proteins whose median level varied significantly among the different delivery groups (Kruskal-Wallis 3 
test; p<0.05). Post-hoc analysis revealed between which of these groups the differences occurred. 4 
The magnitude of these changes (and their associated p values) are presented in tables 2-4. There 5 
were many more proteins with significant differences when comparing samples with inflammation 6 
(PTLi) with other groups; there were 105 proteins with altered expression between TNL and PTLi, but 7 
only 6 when comparing TNL with PTLn. 8 
Proteins involved in prostaglandin synthesis, transport and degradation were detected. These 9 
included the transporter SLCO2A1, two enzymes involved in prostaglandin degradation HPGD and 10 
CBR1 (carbonyl reductase 1), and the prostaglandin synthases PTGES, PTGES2, PTGES3, and PTGDS. 11 
PTGS2 was not detected in any of the samples. None of these proteins altered significantly when 12 
comparing the delivery groups, except the enzyme 15-hydroxyprostaglandin dehydrogenase (HPGD). 13 
This enzyme was detected in all 20 samples and the median level was significantly reduced in the 14 
smokers relative to the non-smokers (0.43 fold, p=0.016).  15 
 9 
 
The differences in protein expression between the smokers and non-smokers, and between those 1 
with and without evidence of inflammation can be seen in figure 1 and figure 2, respectively. In 2 
these volcano plots each point represents a protein detected by proteomic analysis. 3 
Myeloperoxidase (MPO), a peroxidase enzyme abundantly expressed in neutrophil granulocytes and 4 
associated with inflammation, can be seen in the top right of the volcano plot in figure 1 showing 5 
that MPO is significantly higher in the ACD samples from women with infectious/inflammatory 6 
processes. HPGD can be seen in the top left of the volcano plot comparing the smokers and non-7 
smokers (figure 2), showing that the level of HPGD in the smokers is significantly reduced. 8 
  9 
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Table 2 Protein changes associated with spontaneous labor at term 1 
Accession 
number 
Gene 
symbol 
Description Ratio 
TNL:TL 
 
p value 
B7Z4R8 PRG4 Proteoglycan-4 3.36 0.016 
P0C0L5 C4B Complement C4-B  1.91 0.042 
A8K5J8 C1R Complement C1R subcomponent 1.58 0.037 
P62306 SNRPF Small nuclear ribonucleoprotein F  1.28 0.017 
B4DKI2 SORB cDNA FLJ60282, highly similar to Sorbitol dehydrogenase  1.20 0.038 
B4E2S3 RFTN1 Raftlin  0.77 0.043 
P49411 TUFM Elongation factor Tu, mitochondrial  0.76 0.023 
P54577 YARS Tyrosine--tRNA ligase, cytoplasmic  0.72 0.038 
P62070 RRAS2 Ras-related protein R-Ras2 0.66 0.038 
K7ENK9 VAMP2 Vesicle-associated membrane protein 2 0.64 0.028 
F8W8T1 MX1 Interferon-induced GTP-binding protein Mx1  0.58 0.017 
Q14166 TTLL12 Tubulin--tyrosine ligase-like protein 12  0.57 0.045 
P05161 ISG15 Ubiquitin-like protein ISG15  0.45 0.041 
P00966 ASS1 Argininosuccinate synthase  0.31 0.045 
  2 
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Table 3 Proteins altered by the presence of inflammation. For brevity, only proteins with at least a 2-fold 1 
difference are shown. 2 
Accession 
number 
Gene symbol Description Ratio 
TNL:PTLi 
p value 
P17213 BPI Bactericidal permeability-increasing protein  21.46 0.007 
C9JZR7 ACTB Actin, cytoplasmic 1  18.66 0.016 
B2MUD5 ELA2 Neutrophil elastase 15.54 0.003 
B2R4M6 S100 Protein S100  15.43 0.002 
P59666 DEFA3 Neutrophil defensin 3  10.53 0.029 
P05164 MPO Myeloperoxidase  10.22 0.008 
P27216 ANXA13 Annexin A13  10.13 0.024 
P80188 LCN2 Neutrophil gelatinase-associated lipocalin  10.13 0.002 
Q96IS6 HSPA8 HSPA8 protein 8.73 0.003 
P08311 CTSG Cathepsin G 8.58 0.006 
P05109 S100A8 Protein S100-A8  7.67 0.014 
P54108 CRISP3 Cysteine-rich secretory protein 3 7.01 0.016 
Q9NS13 APOB48R Placenta apolipoprotein B48 receptor type 2 6.42 0.009 
B3KTE6 CHI3L1 Chitinase-3-like protein 1  6.34 0.034 
P49913 CAMP Cathelicidin antimicrobial peptide  5.99 0.003 
E7EQB2 LTF Lactotransferrin 5.45 0.021 
Q6P4A8 PLBD1 Phospholipase B-like 1  5.17 0.023 
H7C2Z6 GCA Grancalcin 4.91 0.016 
P52790 HK3 Hexokinase-3 4.73 0.038 
P43490 NAMPT Nicotinamide phosphoribosyltransferase  4.29 0.002 
P14317 HCLS1 Hematopoietic lineage cell-specific protein  3.87 0.032 
A0A024R936 NCF2 Neutrophil cytosolic factor 2 (65kDa, chronic granulomatous 
disease, autosomal 2), isoform CRA_a  
3.73 0.012 
E9PAQ1 CFP Properdin  3.44 0.034 
P31146 CORO1A Coronin-1A  3.43 0.014 
O00160 MYO1F Unconventional myosin-If  3.02 0.023 
P16401 HIST1H1B Histone H1.5  2.98 0.003 
P12429 ANXA3 Annexin A3  2.97 0.015 
X6R433 PTPRC Receptor-type tyrosine-protein phosphatase C  2.93 0.027 
Q10588 BST1 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2  2.68 0.041 
P20700 LMNB1 Lamin-B1 2.53 0.01 
B3KSI4 TKT Transketolase 2.41 0.012 
A0A024RAJ8 IQGAP2 IQ motif containing GTPase activating protein 2, isoform 
CRA_b  
2.32 0.012 
C9JQ42 GYG1 Glycogenin-1 2.24 0.021 
Q08722 CD47 Leukocyte surface antigen CD47 2.19 0.013 
B5BU83 STMN1 Stathmin  2.15 0.011 
P13796 LCP1 Plastin-2  2.12 0.049 
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P16402 HIST1H1D Histone H1.3  2.06 0.028 
P08133 ANXA6 Annexin A6  2.01 0.022 
A6XND0 IGFBP3 Insulin-like growth factor binding protein 3  0.50 0.013 
Q8IV56 PRR15 Proline-rich protein 15  0.50 0.04 
E4W6B6 RPL27 RPL27/NME2 fusion protein 0.49 0.036 
J3QSB5 RPL36 60S ribosomal protein L36 0.49 0.009 
P04181 OAT Ornithine aminotransferase, mitochondrial  0.46 0.025 
P35237 SERPINB6 Serpin B6  0.44 0.027 
C9J7T7 NCOR2 Nuclear receptor corepressor 2  0.43 0.03 
O94907 DKK1 Dickkopf-related protein 1  0.41 0.013 
B4DP54 TUBB6 Tubulin beta-6 chain  0.41 0.007 
P50479 PDLIM4 PDZ and LIM domain protein 4 0.23 0.013 
 1 
  2 
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Table 4 Proteins altered by maternal smoking. For brevity, only proteins with at least a 2-fold difference are 1 
shown. 2 
  3 
Accession 
number 
Gene 
symbol 
Description Ratio 
Smokers:non-
smokers 
p 
value 
A2NX48 BPI' Bactericidal /Permeability Increasing Protein 8.69 0.005 
Q6P4A8 PLBD1 Phospholipase B-like 1 3.63 0.024 
P27105 STOM Erythrocyte band 7 integral membrane protein 2.61 0.017 
P17948 FLT1 Vascular endothelial growth factor receptor 1 0.48 0.003 
Q6P988 NOTUM Protein notum homolog 0.47 0.005 
H0YK49 ETFA Electron transfer flavoprotein subunit alpha, 
mitochondrial 0.47 0.037 
J3QRL9 DSC3 Desmocollin-3  0.45 0.037 
P15428 HPGD 15-hydroxyprostaglandin dehydrogenase 0.43 0.016 
E7EPP8 CYP11A1 Cholesterol side-chain cleavage enzyme, 
mitochondrial 0.40 0.030 
I3L3H2 EIF4A3 Eukaryotic initiation factor 4A-III 0.39 0.037 
A0A024R6I7 SERPINA1 Alpha-1-antitrypsin 0.24 0.003 
 14 
 
Figure 1 Volcano plot to show difference in protein expression between ACD samples with evidence of 1 
inflammation/infection and those without. The X axis represents the fold difference, with those furthest from the 2 
midline the point showing greatest differences between the two groups. The axis is logarithmically converted so that log2 3 
(fold difference) is plotted. Therefore a plotted value of greater than 1 or less than -1 indicates a fold difference of more 4 
than 2. log2 (fold difference) > 2.5 correlates to fold difference >5.7. The Y axis represents the p value. It is shown as –log10 5 
(p value) and therefore the higher the point the more statistically significant the difference between the two groups. -log10 6 
(p value) >1.3 correlates to p value <0.05. Proteins with larger fold differences that had p values <0.05 (-log10 (p value) 7 
>1.3) are labelled with their gene names and marked with rhomboids. 8 
 9 
  10 
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Figure 2 Volcano plot to show difference in protein expression between those ACD samples from smokers and non-1 
smokers. The X axis represents the fold difference, with those furthest from the midline point showing greatest differences 2 
between the two groups. The axis is logarithmically converted so that log2 (fold difference) is plotted. Therefore a plotted 3 
value of greater than 1 or less than -1 indicates a fold difference of more than 2. The Y axis represents the p value. It is 4 
shown as –log10 (p value) and therefore the higher the point the more statistically significant the difference between the 5 
two groups. -log10 (p value) >1.3 correlates to p value <0.05. Proteins with larger fold differences that had p values <0.05 6 
are labelled with their gene names and marked as rhomboids. 7 
 8 
Discussion 9 
The fetal membranes and decidua have important tasks, not only containing the developing fetus 10 
and amniotic fluid, and providing an essential physical barrier, but also in being the main interface 11 
between mother and baby, ideally situated to receive both maternal and fetal signals as well as 12 
transmit signals to the myometrium [17]. Here we report the investigation of their vital paracrine 13 
functions using tandem mass tagging liquid chromatography mass spectrometry (TMT-LC MS) for the 14 
first time. TMT-LC MS gives quantitative information on the abundance of proteins and doesn’t rely 15 
on the availability of suitable antibodies, a considerable limitation of immunoblotting techniques.  16 
Effects of labor and inflammation 17 
 16 
 
Increased levels of the PG synthases within the labor and inflammation groups were anticipated. The 1 
prostaglandin F synthase AKR1B1 (aldo-keto reductase family 1 member B) was detected in all 20 2 
samples; no differences in this enzyme were discernible when comparing the samples from the labor 3 
and non-labor groups. One explanation for this surprising result is that the decidual component of 4 
the ACD samples is impacting on the AKR1B1 levels [25]. Harper et al. in 1983 described higher 5 
decidual levels of PGF2in pre-labor samples when compared with labor samples [26], so it is 6 
possible that this PGF2 is a consequence of a labor-associated decrease in decidual AKR1B1, which 7 
would balance out any potential increases in the amnion/chorion. Complement-related proteins are 8 
often identified in maternal plasma [27] and are synthesised by ACD tissues [28] but their predictive 9 
value in the timing of the onset of spontaneous labor is poor [29]. We found a modest decrease in 10 
C1R (Complement C1r subcomponent) with labor at term; C1R is involved in the classical pathway of 11 
complement activation. RFTN1 (raftlin) is a lipid raft protein involved in T cell receptor signalling [30] 12 
and our findings suggest it may increase in association with immune activation in labor.   13 
Inflammation caused significant disruption in nearly 50 proteins in ACD which is a reflection of the 14 
activation of resident ACD macrophages and infiltrating leukocytes previously studied at the 15 
transcriptomic level [31, 32]. The observed increase in MPO (myeloperoxidase; part of the leukocyte 16 
defense system) with inflammatory changes is reassuring; MPO levels in amniotic fluid have been 17 
shown to increase in chorioamnionitis, most likely representing high levels of neutrophil activation 18 
and degranulation [33, 34]. Labor did not affect MPO expression. The effect of labor on MPO 19 
expression in ACD has not previously been investigated. Many authors have suggested a degree of 20 
inflammatory activity is associated with normal labor [35-37]; Haddad et al. found that labor 21 
produced gene expression changes in keeping with localised inflammation [38], even when 22 
histologically detectable inflammation was absent. Whilst spontaneous labor has been associated 23 
with elevated levels of chemokines known to be involved in monocyte recruitment [38], neutrophil 24 
infiltration and activation leading to MPO production are not thought to be a significant component 25 
 17 
 
of the initiation of labor. Myometrial inflammation is likely to be a consequence rather than a cause 1 
of labor [39].  2 
Effects of smoking 3 
Smoking has previously been shown to increase fetal membrane and amniotic fluid levels of PGF2α, 4 
PGE2, PGD2 and the prostaglandin-like F2-isoprostane, a marker for oxidative stress [13, 40]. In our 5 
study, maternal smoking significantly affected expression of the key enzyme involved in the 6 
inactivation of prostaglandins, 15-hydroxy prostaglandin dehydrogenase (HPGD) [41]; ACD samples 7 
from smokers had less than half the level of HPGD than those from the non-smokers (figure 2).  8 
Genetically modified mice with decreased expression of HPGD deliver prematurely without 9 
progesterone-withdrawal [42]. In these animals the onset of labor was preceded by increased 10 
concentrations of PGE2 and PGF2α. The exact role of HPGD in initiating labor is unclear. Whilst 11 
several authors have described lower levels of HPGD expression in the fetal membranes in 12 
association with labor [32, 43, 44], others have reported no labor-associated change in the 13 
expression and activity of the enzyme [45] or an increase in labor-associated activity [46]. Some 14 
authors have proposed that there is an altered expression of HPGD in preterm labor, with 15-20% of 15 
patients in idiopathic preterm labor exhibiting decreased HPGD protein in the chorion as well as 16 
reduced HPGD activity [43]. With infection-associated PTL both no change [43] and reduced activity 17 
and expression of HPGD have been reported [32, 45]. Johnson et al. suggest that the variation in 18 
these findings is due to the in vitro nature of much of this work [41]; HPGD protein turnover is rapid 19 
and altered by some of the agonists used in cell culture. Using primers that recognise all splice 20 
variants they showed that the total abundance of HPGD mRNA did not change with labor. There was 21 
no effect of labor, inflammatory status or gestational age on the HPGD levels in our ACD samples. 22 
The effect of maternal smoking on HPGD expression is a novel interesting finding. We are unaware 23 
of any studies that have examined the effect of tobacco smoke on HPGD expression. Furthermore, 24 
those studies that looked at the effect of gestational age, labor and inflammatory status on HPGD 25 
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expression [32, 43-45] did not appear to have considered maternal smoking as a co-factor. We 1 
propose that the reduced expression of HPGD associated with smoking is a novel mechanism 2 
through which smoking may contribute to preterm labor. Lower levels of this enzyme, key to 3 
metabolising prostaglandins, may result in higher levels of prostaglandins and therefore precipitate 4 
labor prematurely.  5 
Limitations 6 
The limitations of using self-reported smoking behaviour to define smokers are well documented 7 
[47-49] and objective measures of smoking exposure may be preferable. Exhaled carbon monoxide 8 
(eCO) readings have been shown to be reliable in differentiating smokers from non-smokers [50-52]. 9 
Whilst some women had first trimester eCO readings available, more than half did not. Smoking 10 
status was therefore defined by self-report despite its limitations. Furthermore, the importance of 11 
environmental tobacco smoke exposure on pregnancy outcomes is increasingly being recognised 12 
[53] as well as an individual’s past smoking habits. Future work on the effect of smoking on 13 
gestational tissues’ protein expression should give consideration to the use of biochemical measures 14 
to define smoking exposure, both direct and passive. Serum or hair cotinine or nicotine levels have 15 
the ability to give exposure information on greater timeframes than eCO [49].  16 
Chorioamnionitis, as determined by histopathological examination of the placental tissues, is 17 
clinically silent in the majority of women [54]. In our data, half of the samples subsequently found to 18 
have histopathological features suggestive of acute infection (presence of leucocyte infiltration in 19 
the fetal membranes, decidua or placenta) came from women with no clinical signs or symptoms of 20 
chorioamnionitis. Placental swab culture, including bacterial PCR testing could be used in 21 
conjunction with measuring the expression of other proteins known to be involved in inflammatory 22 
responses such as interleukin 8, S100 calcium binding protein A8 and Toll-like receptor 2 [32] to 23 
further facilitate classification of the samples. Whilst median levels of MPO were found to be raised 24 
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in the inflammatory group, values were too varied to use this measure to further categorise the 1 
samples. 2 
This paper confirms the potential of TMT proteomics to identify multiple protein changes in ACD in 3 
relation to labor, inflammation and smoking. It is important to use reliable validated databases and 4 
an accepted, stringent false discovery rates (FDR) estimation. Here we have used a recommended 5 
FDR of 5% [55]. However, even assuming reliable identiﬁcation and quantiﬁcation of a protein, the 6 
data doesn’t inform us of its biological activity. There are considerable splice variants and post-7 
translational modifications that alter the functionality of a protein; many proteins have multiple 8 
functions or may exist as active and inactive isoforms [55]. In some cases proteins known to be 9 
present in the samples may not be detected by TMT-LC MS. This may either be because there are 10 
insufficient amounts in the sample, because a given peptide’s signal is masked by another peptide’s 11 
signal within the mass spectrometer, or because a certain protein does not produce tryptic peptides 12 
of a suitable size. 13 
Despite these limitations proteomics is a powerful tool for the discovery of new proteins of interest. 14 
Our finding of lower HPGD levels in the ACD samples from smokers raises important questions 15 
regarding the effect of smoking on the mechanism of preterm labor. Further research is required, 16 
including the use of functional assays to demonstrate any effect of smoking on the activity of HPGD, 17 
and the range of prostaglandin metabolites produced.  18 
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